Similarly, ODC1 inhibition by difluoromethylornithine (DFMO) has shown promising results, both in vitro and in vivo, and it is being evaluated in previous phase II clinical trials for NB patients [105]. The gene discussed is ODC1; the disease is neuroblastoma.